EXELIXIS Q3 2026 FINANCIAL RESULTS CONFERENCE CALL - EXELIXIS INC

Explicit Guidance:

• Full-Year 2026 Gross-to-Net Deductions: Updated estimate projected at approximately 30%, driven by lower 340B discounts compared to Q2 and revised cost of goods sold (COGS) assumptions.
• Full-Year 2026 Financial Guidance: Maintained for total revenue and operating metrics, though specific numbers were not restated in the transcript; guidance reflects adjustments to COGS and tax rate estimates.
• Tax Rate: Updated provision for Q3 2026 was $64.7 million (vs. $50.6M in Q2). Management expects the long-term effective tax rate to be at the federal rate or thereabouts, excluding the Q4 adjustment related to tax return filing.
• Capital Allocation: $250 million repurchased in Q3 2026 (4.5 million shares); $348 million remaining under a $750 million authorized plan as of Q3 2027.

Business-Segment Outlook:

• Cabo Franchise (Cabo-Medics):
  • RCC: Maintained as the number one TKI and number one TKI+IO combination in first-line; strong growth in first-line 9ER data.
  • NET (Neuroendocrine Tumors): Second-line plus oral market share now >50%; demand growing with patient accumulation driven by refills and new patient market share; expanded GI sales team active for a second full quarter with >1,000 unique prescribers activated.
  • Trend: Sequential growth expected in Q4 driven by "indolent" disease kinetics and long duration of therapy in NET.
• Zanza Franchise (Zanzalitinib):
  • CRC (Colorectal Cancer): Positioning for launch in 3rd-line plus setting (approx. 23,000 U.S. patients, $1.5B TAM at contemporary pricing); expected to be the first IO+TKI combination in this setting with ~70% prescriber overlap with Cabo (90% including co-location).
  • RCC (Renal Cell Carcinoma): Focus on non-clear cell (Stellar 304 results expected Q1 2027) and clear cell (Merck LightSpark trials); aiming to make Zanza the market leader in "3rd-line plus" kidney cancer.
  • Pipeline Expansion: Goal to build a "durable franchise" via "stacking capabilities" across GU, GI, and other indications, leveraging 7 ongoing "Wave 1" trials and planning "Wave 2" pivotal studies.

Market and Competitive Outlook:

• Competitive Positioning: Cabo maintains leadership in oral TKI market basket (TRX volume grew 13% vs. market 6% in Q3); Zanza positioned to displace existing oral agents in NET frontline if Stellar 311 data is positive.
• Pricing & Market Dynamics: 340B program impact deemed minimal due to integrity agreements; market access team actively managing double-counting risks.
• Unmet Needs: High demand in metastatic CRC 3rd-line plus, clear cell RCC (post-adjuvant/triple therapy failures), bladder cancer (post-EV/Pembrolizumab), and neuro-oncology (recurrent meningioma).

Macro / Industry Outlook:

• Regulatory Environment:
  • NDA PDUFA Date: March 3, 2027, for the CRC indication (Stellar 304).
  • Drug Pricing: Management referenced monitoring government drug pricing policies but did not specify quantitative macro-economic impacts beyond standard 340B dynamics.
• Supply Chain/Operations: No major supply constraints anticipated; focus on "rigorous expense management" and "capital allocation."

Strategic Initiatives:

• Clinical Development (Zanza Wave 1):
  • Stellar 316 (CRC): Enrolling; investigating Zanza + subQ Pembro vs. Zanza alone vs. Pembro alone in resected stage II/III MSI-stable CRC (Molecular Residual Disease positive).
  • Stellar 311 (NET): Global Phase 3 vs. Everolimus (first/only small molecule vs. active control); aiming to be first oral therapy in this indication.
  • Stellar 304 (RCC - Non-Clear Cell): Top-line results expected Q1 2027; potential for second NDA filing.
  • Stellar 201 (Meningioma): Phase 2; high unmet need driving enrollment > projections.
  • Stellar 303 (CRC - 3L+): Pivotal data generated; preparing for launch.
• Clinical Development (Zanza Wave 2 & Combinations):
  • Lung Cancer: Stellar 203 initiated (maintenance after induction) testing Zanza + Pembrolizumab in squamous NSCLC.
  • Bladder Cancer: Investigating Zanza + PD-1 in patients previously treated with Enfortumab Vedotin + PD-1 (Stellar 002 cohort); fastest enrollment seen.
  • Bispecifics: Enrolling safety cohort of Zanza + XB628 (novel bispecific); expansion cohorts for GU/GI planned soon.
  • Chemotherapy: Evaluating Zanza + Docetaxel in mCRPC (expansion cohort Stellar 002); rationale based on Cabo+Docetaxel data.
• New Assets:
  • XL558: New development candidate (selective SSTR2 agonist); IND submission planned later this year.
  • Partnerships: Discussions ongoing to combine Zanza with novel molecules from external partners, focusing on GU/GI.
• Timeline: Key inflection points anticipated with PDUFA (March 2027), Stellar 304 top-line (Q1 2027), and Stellar 316/311 enrollment progress.

Risks and Headwinds to Outlook:

• Clinical Trial Execution: Risk of delays or negative data in Wave 1 and 2 trials (e.g., Stellar 304 readout timing, LightSpark 33/34 outcomes with Merck).
• Regulatory Uncertainty: FDA interactions regarding labeling (currently in ongoing review for NDA); PDUFA dates subject to change.
• Commercial Execution: Potential impact of competitive launches in earlier-line CRC and RCC; 340B program evolution (though currently deemed low risk).
• Operational: "Choppy" nature of clinical trial revenues (historical volatility); higher Q4 operating expenses (legal, marketing, COGS).
• Financial: Tax rate adjustments (Q4 specific) and COGS fluctuations impacting gross-to-net margins.

Management Tone on the Future:

• Confidence Level: High confidence in Zanza's "differentiated profile" and "potential to drive growth for years."
• Strategic Focus: "Laser-focused" on advancing Zanza to become a major franchise; "unwavering" commitment to expense management and capital returns.
• Sentiment: Described as a "potentially transformational time"; palpable excitement around Stellar 303 data and launch preparation.
• Comparison to Prior Guidance: Maintained full-year revenue guidance despite strong Q3 Cabo growth, citing the "temporal nature" of NET growth and revenue timing as per previous quarters.

Miscellaneous:

• M&A/Collaboration: Active discussions with collaborators for Zanza combination studies; Merck partnership remains critical for RCC (LightSpark trials).
• Product Lifecycle: Cabo franchise (10+ years post-launch) continues to reinforce the company's ability to build and commercialize oncology franchises; Zanza strategy modeled after Cabo's 14 pivotal trials and 8 approvals.